Примери за използване на Paediatric indication на Английски и техните преводи на Български
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Paediatric indication.
Current available safety data for other paediatric indications are described in section 4.8.
Paediatric indications were agreed in the following indications: .
Applications for a marketing authorisation that includes a paediatric indication;
Other paediatric indications.
A new type of marketing authorisation, the paediatric use marketing authorisation(PUMA),to incentivise the development of paediatric indications for off-patent products;
In addition the paediatric indications have been clarified.
The CHMP considered that open label studies are not appropriate to demonstrate long term efficacy for regulatory purposes, andthat a single study cannot be sufficient to support a paediatric indication.
In one MS, the paediatric indication is restricted to recurrent upper RTI(RURTI).
Since no new data was submitted during this harmonisation referral,the CHMP confirmed that a paediatric indication could not be granted during this Article 30 harmonisation referral.
Depending on MS, the paediatric indication covers children from 1 year, 6 months, or without restrictions.
Because the reward is for conducting studies in children and not for demonstrating that a product is safe and effective in children,the reward will be granted even when a paediatric indication is not granted.
Applications to include a paediatric indication in an existing marketing authorisation;
In view of the submitted data and the clinical experience of the safety and efficacy of piperacillin-tazobactam in neutropenic and nonneutropenic children,the CHMP considered the inclusion of the paediatric indications in neutropenic children to be justified.
By the end of 2011, 72 new paediatric indications had been approved for already authorised medicines.
(28) Because the reward is for conducting studies in the paediatric population and not for demonstrating that a product is safe and effective in the paediatric population,the reward should be granted even when a paediatric indication is not authorised.
Concerns were further raised with regards to the Paediatric Indication and the use of the comparator Magnevist.
The paediatric indication was not granted during the assessment of paediatric data through the EU worksharing procedure.
However, the treatment regimen and posology in these paediatric indications should be chosen according to the local standard of care.
The current paediatric indications are not disharmonised based on the indication itself but with regards to the definition of the paediatric age groups and with regards to the dosing for these groups.
Where a medicinal product is granted a marketing authorisation for a paediatric indication, the label shall display the symbol agreed in accordance with paragraph 2.
The provisions of this Article shall also apply to medicinal products authorised before the entry into force of this Regulation, and to medicinal products authorised after the entry into force of this Regulation but before the symbol has been made public,if they are authorised for paediatric indications.
One single study was submitted in support of the paediatric indication, a 12 week randomised double blind study with a sertraline and a placebo arm.
Applications may be submitted in accordance with the procedure laid down in Articles 5 to 15 of Regulation(EC)No 726/2004 for a marketing authorisation as referred to in Article 7(1) of this Regulation which includes one or more paediatric indications on the basis of studies conducted in compliance with an agreed paediatric investigation plan.
The Marketing Authorisations Holders of products for which a paediatric indication is approved shall submit the protocols of new or ongoing studies to the National Competent Authorities within 4 months of the commission decision for this procedure.
Article 28 of the Regulation sets out where authorisation is granted, the results of all those studies shall be included in the SmPC and, if appropriate, in the PL of the medicinal product, provided that the competent authority deems the information to be of use to patients,whether or not all the paediatric indications concerned were approved by the competent authority.
The SAG Psychiatry was consulted on the clinical value of the following adult and paediatric indications(section 4.1) and also on dosing recommendations in clinical practice(section 4.2).
Where authorisation is granted, the results of all those studies shall be included in the summary of product characteristics and, if appropriate, in the package leaflet of the medicinal product, provided that the competent authority deems the information to be of use to patients,whether or not all the paediatric indications concerned were approved by the competent authority.
Such a reward also applies in those cases where completion of the agreed PIP failed to lead to the authorisation of a paediatric indication, but“the results of the studies conducted are reflected in the summary of product characteristics and, if appropriate, in the package leaflet of the medicinal product concerned”.
In the case of authorised medicinal products which are protected either by a supplementary protection certificate under Regulation(EEC) No 1768/92, or by a patent which qualifies for the granting of the supplementary protection certificate, Article 7 of this Regulation shall apply to applications forauthorisation of new indications, including paediatric indications, new pharmaceutical forms and new routes of administration.